More recently, IMpower010 showed a disease‐free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stage II–IIIA NSCLC, with pronounced benefit in the subgroup whose tumours expressed programmed death ligand 1 (PD‐L1) on 1% or more of tumour cells.13 This evidence concerns the gene CD274 and neoplasm.